MX9800821A - Aislamiento y/o conservacion de celulas dentriticas para la inmunoterapia del cancer de la prostata. - Google Patents
Aislamiento y/o conservacion de celulas dentriticas para la inmunoterapia del cancer de la prostata.Info
- Publication number
- MX9800821A MX9800821A MX9800821A MX9800821A MX9800821A MX 9800821 A MX9800821 A MX 9800821A MX 9800821 A MX9800821 A MX 9800821A MX 9800821 A MX9800821 A MX 9800821A MX 9800821 A MX9800821 A MX 9800821A
- Authority
- MX
- Mexico
- Prior art keywords
- prostate cancer
- dendritic cells
- cells
- human dendritic
- activate
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title abstract 6
- 206010060862 Prostate cancer Diseases 0.000 title abstract 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 5
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 238000002955 isolation Methods 0.000 title 1
- 238000004321 preservation Methods 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 230000005867 T cell response Effects 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464495—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/58—Prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se presentan métodos y composiciones para el uso de células dentríticas humanas para activar las células T para respuesta inmunoterapéuticas contra cáncer de prostata primario y metastásico. En una modalidad, células dentríticas humanas, después de exposicion a un antígeno de cáncer de la prostata o bien a un péptido antígenico específico, se administran a un paciente con cáncer de prostata para activar las respuestas de las células T relevantes in vivo. En una modalidad alternativa, se exponen células dentríticas humanas a un antígeno de cáncer de prostata o bien a un péptido antigénico específico in vitro y se incuban o cultivan con células T cebadas o no cebadas para activar las respuestas de las células T relevantes in vitro. Las células T activadas se administran después a un paciente con cáncer de prostata. Se presentan métodos y composiciones para células dentríticas humanas, con una duracion de vida extendida y células dentríticas conservadas en condiciones criogénicas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/509,254 US5788963A (en) | 1995-07-31 | 1995-07-31 | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| US08509254 | 1995-07-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX9800821A true MX9800821A (es) | 1998-10-31 |
| MXPA98000821A MXPA98000821A (es) | 1999-01-11 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| NZ315441A (en) | 1999-06-29 |
| CA2228176C (en) | 2015-05-26 |
| EP0841940A4 (en) | 2005-01-05 |
| AU6714696A (en) | 1997-02-26 |
| JP2001520633A (ja) | 2001-10-30 |
| DE841940T1 (de) | 2001-08-23 |
| EP2377548A3 (en) | 2012-10-10 |
| US20130017600A1 (en) | 2013-01-17 |
| EP0841940A1 (en) | 1998-05-20 |
| US5788963A (en) | 1998-08-04 |
| IL123079A0 (en) | 1998-09-24 |
| WO1997004802A1 (en) | 1997-02-13 |
| AU723607B2 (en) | 2000-08-31 |
| CA2228176A1 (en) | 1997-02-13 |
| EP2377548A2 (en) | 2011-10-19 |
| JP4267692B2 (ja) | 2009-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2377548A3 (en) | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy | |
| DK0870022T3 (da) | Immunstimulerende sammensætning og fremgangsmåde | |
| NZ333607A (en) | Method of stimulating the immune system by transfecting dendritic cells | |
| ES2112860T3 (es) | Inmunoterapia adoptiva con interleukina-7. | |
| HK1086750A1 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
| AU2953895A (en) | Multi-stage cascade boosting vaccine | |
| ATE432085T1 (de) | Stimulationsfaktor für dendriten | |
| SG49113A1 (en) | Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl | |
| NZ514228A (en) | Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation | |
| WO1998033527A3 (en) | Cancer immunotherapy with semi-allogeneic cells | |
| NO965395L (no) | Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen | |
| MX9603431A (es) | Peptidos reconocidos por linfocitos citotoxicos, especificos al melanoma, y los usos para los mismos. | |
| NZ505834A (en) | Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use | |
| TR200102034T2 (tr) | Anti kanser aşılaması için antikorların kullanılması | |
| EP0202642A3 (en) | Process for the in vitro immunization of human splenocytes against tumor associated antigens | |
| AU2883597A (en) | Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy | |
| IL165250A0 (en) | Methods of donor specific crossmatching | |
| WO1997023607A3 (en) | Presentation of antigen, introduced into cells by stimulation of macropinocytosis | |
| Haubeck et al. | Analysis of T suppressor cell-mediated tumor escape mechanisms is facilitated by the selective in vitro activation of tumor-specific Ts cells | |
| LU | Analysis of T Suppressor Cell-Mediated Tumor Escape Mechanisms Is Facilitated by the Selective In Vitro Activation of Tumor-specific Ts Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GB | Transfer or rights |